Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.54 |
| ▸ | AGXT | P21549 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 7/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | HTR3A | P46098 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25524602 | 0.86 | PRMT6 (0.49) | AGXTKDM4EALDH1A1GFERL3MBTL1 | |
| SCHEMBL11955062 | 0.83 | ADRA2C (0.61) | ADRA2CAGXTHTR2CHTR1AHTR2A | |
| SCHEMBL783346 | 0.81 | ADRA2C (0.62) | ADRA2CAGXTHTR2CHTR1AHTR2A | |
| SCHEMBL6851591 | 0.81 | ADRA2C (0.62) | ADRA2CAGXTHTR2CHTR1AHTR2A | |
| SCHEMBL28797389 | 0.81 | ADRA2C (0.62) | ADRA2CAGXTHTR2CHTR1AHTR2A | |
| SCHEMBL11984298 | 0.80 | ALDH1A1 (0.52) | ADRA2CKDM4EALDH1A1GFERL3MBTL1 | |
| SCHEMBL11990304 | 0.80 | ALDH1A1 (0.52) | ADRA2CKDM4EALDH1A1GFERL3MBTL1 | |
| SCHEMBL19710909 | 0.79 | RORC (0.43) | KDM4EALDH1A1GFERL3MBTL1LMNA | |
| SCHEMBL24781211 | 0.77 | HDAC4 (0.39) | KDM4EALDH1A1GFERL3MBTL1LMNA | |
| SCHEMBL16019525 | 0.76 | NOTUM (0.56) | ADRA2CDRD3KDM4EALDH1A1GFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-12-22 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | ADRA2C 4227/4885AGXT 3767/4885HTR2C 4652/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | ADRA2C 4521/4885AGXT 2551/4885HTR2C 4427/4885 |
| US-20220402869-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | ADRA2C 3179/4885AGXT 1706/4885HTR2C 4123/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.